Table 2.
Outcome | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
---|---|---|---|---|---|
ESRD* | |||||
Males | 7.1 (4.4–10.8) | 9.6 (6.9–15.1) | 15.9 (11.1–21.6) | 18.3 (12.9–24.4) | 22.3 (16.0–29.3)# |
Females | 5.9 (4.9–6.9) | 10.4 (9.1–11.8) | 13.9 (12.8–15.5) | 17.8 (15.9–19.7) | 21.2 (19.0–23.5) |
Mortality | |||||
Males | 2.8 (1.3–5.5) | 4.7 (2.3–8.2) | 7.4 (4.2–12.0) | 8.4 (4.8–13.4) | 9.4 (5.4–14.9)## |
Females | 3.7 (3.0–4.7) | 5.8 (4.8–6.8) | 7.0 (5.9–8.3) | 8.0 (6.8–9.4) | 9.8 (8.3–11.5) |
ESRD analysis accounts for the competing risk of death
4.77 years,
4.5 years